Rituximab and Ocrevus had similar MS brain scan results
Key Takeaway
Rituximab and Ocrevus had similar brain scan results in adults with newly diagnosed relapsing MS.
What They Found
From months 6 to 24, about 92% of the rituximab group had no new or growing spots on brain scans. About 95% of the ocrelizumab (Ocrevus) group had the same result. Relapse rates, disability, and thinking test results appeared similar between groups. Infections occurred in 82% of the rituximab group and 69% of the Ocrevus group. Serious health problems were reported in 8% and 7% of the groups, respectively.
Who Should Care and Why
The study included adults with newly diagnosed relapsing MS who had recent disease activity. Researchers compared rituximab with Ocrevus, two drugs used to treat MS. Participants received their assigned drug every six months. The main comparison was whether new or growing spots appeared on brain scans. The findings are most relevant to people with newly diagnosed relapsing MS and recent disease activity.
Important Considerations
This was a randomized trial (a study that assigns treatments by chance) with 218 adults; 216 received treatment. You cannot tell from these results whether the drugs have similar effects beyond 24 months. You should also know that infections were more common with rituximab, despite similar rates of serious health problems.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
9/29/2026
A review shows how patient surveys are used in MS care, why answers may not lead to action, and what
Read More
9/28/2026
A review of 17 people with worsening weakness found rare brain lesions along movement pathways. Some
Read More
9/28/2026
In 179 people with MS, narrower eye blood vessels were linked to greater disability. Combining vesse
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like The New England journal of medicine often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.